GO:0005152 interleukin-1 receptor antagonist activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005152 (interleukin-1 receptor antagonist activity) is a molecular function defined as blocking the binding of interleukin-1 to the interleukin-1 receptor complex.
• The prototype protein carrying this activity is IL1RN (IL-1ra), a naturally occurring antagonist that competes with IL-1α and IL-1β for the IL-1 receptor.
• IL-1ra is a member of the interleukin-1 family and acts as an endogenous anti-inflammatory regulator by preventing IL-1R1 engagement and downstream NF-κB and MAPK signaling.
• Beyond canonical IL-1R1 blockade, IL-1ra can bind alternative targets such as muscarinic receptor 4 (CHRM4), which has been linked to immunosuppression and neuroendocrine differentiation in prostate cancer.
• IL-1ra can modulate distinct cell death pathways, and its activity is sensitive to proteolytic cleavage, as shown for alteplase-mediated cleavage impairing neuroprotection in ischemic stroke.
• Therapeutic delivery of IL-1ra is an active area, with injectable biomaterials developed to improve its stability and therapeutic effect.
Description
Interleukin-1 receptor antagonist activity (GO:0005152) is a molecular function that blocks the binding of interleukin-1 to the interleukin-1 receptor complex. This activity is essential for controlling the intensity and duration of IL-1-driven inflammation, because it provides a natural brake on one of the most potent pro-inflammatory cytokine systems in the body. The prototype protein that carries this function is the interleukin-1 receptor antagonist (IL-1ra), encoded by the IL1RN gene, which competes with IL-1α and IL-1β for occupancy of the IL-1 receptor without triggering signaling. Researchers study GO:0005152 because dysregulated IL-1 signaling contributes to a wide range of human diseases, including autoinflammatory disorders, cancer, and ischemic injury. The antagonist activity is not simply a passive decoy; structural and computational studies show that IL-1ra binding can influence cell death pathways and that its own stability and cleavage state determine its protective capacity. In addition, IL-1ra has been reported to interact with non-canonical partners such as CHRM4, expanding its functional repertoire beyond IL-1 receptor blockade. From a therapeutic perspective, recombinant IL-1ra (anakinra) and biomaterial-based delivery systems are being developed to harness this activity for clinical benefit. Understanding the molecular details of GO:0005152, including which genes encode the relevant proteins and how the activity is regulated, is therefore central to both basic immunology and translational medicine.
interleukin-1 receptor antagonist activity At A Glance
| GO ID | GO:0005152 |
|---|---|
| GO term | interleukin-1 receptor antagonist activity |
| Ontology | molecular_function |
| Synonym | IL-1ra |
| Definition | Blocks the binding of interleukin-1 to the interleukin-1 receptor complex. |
| Major function | Competitive inhibition of IL-1 receptor occupancy, dampening IL-1-driven inflammation. |
| Prototype protein | IL1RN (IL-1ra), a member of the interleukin-1 family. |
| Related ligands | IL-1α and IL-1β, which are antagonized by this activity. |
| Therapeutic relevance | Recombinant IL-1ra (anakinra) and biomaterial-based delivery systems. |
What Is GO:0005152?
According to the Gene Ontology, GO:0005152 (interleukin-1 receptor antagonist activity) is defined as blocking the binding of interleukin-1 to the interleukin-1 receptor complex. In other words, a protein with this activity prevents IL-1α or IL-1β from productively engaging the IL-1 receptor, thereby attenuating downstream pro-inflammatory signaling. The activity is mediated by the interleukin-1 receptor antagonist (IL-1ra), a cytokine that binds the receptor without activating it.
Why Is interleukin-1 receptor antagonist activity Important in Cell Biology?
GO:0005152 is important because it represents the principal endogenous mechanism for restraining interleukin-1 signaling, a pathway that is central to innate immunity and inflammation. Without this antagonist activity, unchecked IL-1 responses can drive tissue damage, autoinflammation, and tumor-promoting microenvironments. The activity also has direct clinical relevance: recombinant IL-1ra is used therapeutically, and its efficacy can be limited by stability, delivery, and proteolytic cleavage. Moreover, the discovery that IL-1ra can engage non-canonical receptors such as CHRM4 highlights that this activity may have context-dependent roles in cancer biology. Understanding GO:0005152 therefore informs both mechanistic immunology and the design of anti-inflammatory and anti-cancer strategies.
• Provides a natural brake on IL-1α/IL-1β signaling by blocking IL-1 receptor occupancy.
• Prevents excessive NF-κB and MAPK activation downstream of IL-1R1.
• Dysregulation is linked to autoinflammatory and inflammatory diseases.
• IL-1ra can modulate distinct cell death pathways, influencing cell survival decisions.
• Proteolytic cleavage of IL-1ra by alteplase impairs neuroprotection in ischemic stroke.
• IL-1ra binding to CHRM4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
• Injectable biomaterials are being developed to improve IL-1ra delivery and therapeutic effect.
• Erdheim-Chester disease is an inflammatory histiocytosis in which cytokine pathways including IL-1 are relevant.
• The activity is a target for drug development and for CRISPR-based disease modeling.
• Studying GO:0005152 helps dissect the balance between IL-1 agonists and antagonists in disease.
Molecular Mechanism of interleukin-1 receptor antagonist activity
Competitive binding to the IL-1 receptor complex
In simple terms: IL-1ra acts like a key that fits the lock but does not turn it, keeping the real inflammatory keys out.
The core of GO:0005152 is the ability of IL-1ra to occupy the IL-1 receptor complex without activating it, thereby preventing IL-1α and IL-1β from binding and initiating signaling. This competitive antagonism is the defining feature of the activity and is mediated by the IL1RN gene product.
Structural basis of antagonism
In simple terms: The shape of IL-1ra allows it to sit on the receptor but not trigger the changes needed for a signal.
IL-1ra belongs to the interleukin-1 family and shares structural features with IL-1α and IL-1β, yet it lacks the receptor-activating surfaces required to recruit the accessory protein and initiate downstream signaling. Computational studies have explored how IL-1ra binding modulates distinct cell death pathways, indicating that the structural details of the interaction influence cellular outcomes beyond simple receptor blockade.
Downstream signaling suppression
In simple terms: By blocking the receptor, IL-1ra shuts down the inflammatory alarm inside the cell.
When IL-1ra occupies the IL-1 receptor, IL-1 cannot trigger the canonical NF-κB and MAPK cascades that drive pro-inflammatory gene expression. This suppression of downstream signaling is the functional consequence of the antagonist activity and underlies its anti-inflammatory role.
Non-canonical interactions and context dependence
In simple terms: IL-1ra can sometimes bind other proteins, giving it additional jobs beyond blocking IL-1.
Recent work shows that IL-1ra can bind cholinergic receptor muscarinic 4 (CHRM4), and this interaction promotes immunosuppression and neuroendocrine differentiation in prostate cancer. This finding indicates that GO:0005152 may encompass context-dependent functions that extend beyond the classical IL-1 receptor blockade.
Regulation by proteolytic cleavage and delivery
In simple terms: Cutting or delivering IL-1ra in the right way determines whether it can do its job.
The activity of IL-1ra is influenced by its stability and cleavage state; for example, alteplase-mediated cleavage of IL-1ra impairs neuroprotection in ischemic stroke in a timing-dependent manner. Injectable biomaterials have been developed to deliver IL-1ra more effectively, aiming to preserve its antagonist activity for therapeutic benefit.
Key Genes Involved in GO:0005152 interleukin-1 receptor antagonist activity
The following genes and proteins are directly or functionally associated with interleukin-1 receptor antagonist activity (GO:0005152) based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1RN | Encodes the interleukin-1 receptor antagonist (IL-1ra), the prototype protein with GO:0005152 activity. | Central to studies of IL-1 antagonism, autoinflammation, and therapeutic IL-1ra delivery. |
| IL1B | Encodes IL-1β, a pro-inflammatory cytokine whose binding to the IL-1 receptor is blocked by IL-1ra. | Key ligand in IL-1-driven inflammation and a target for antagonist studies. |
| IL1A | Encodes IL-1α, another agonist whose receptor binding is antagonized by IL-1ra. | Relevant to understanding the balance of IL-1 family agonists and antagonists. |
| IL1R1 | Encodes the type I IL-1 receptor that IL-1ra occupies to block IL-1 signaling. | Essential for mechanistic studies of receptor occupancy and downstream signaling. |
| IL1RAP | Encodes the IL-1 receptor accessory protein required for productive IL-1 signaling. | Helps explain why IL-1ra binding does not activate signaling. |
| CHRM4 | Encodes muscarinic receptor 4, a non-canonical binding partner of IL-1ra. | Linked to immunosuppression and neuroendocrine differentiation in prostate cancer. |
| NFKB1 | Encodes a subunit of NF-κB, a downstream transcription factor suppressed when IL-1 signaling is blocked. | Used as a readout of IL-1ra antagonist activity. |
| MAPK1 | Encodes ERK2, part of the MAPK cascade downstream of IL-1 receptor activation. | Serves as a signaling readout for IL-1ra function. |
| MAPK3 | Encodes ERK1, another MAPK component downstream of IL-1 signaling. | Used to monitor suppression of IL-1-induced MAPK activation. |
| CASP3 | Encodes caspase-3, a key executioner of apoptosis. | Relevant to studies of how IL-1ra modulates cell death pathways. |
| CASP8 | Encodes caspase-8, an initiator caspase in extrinsic apoptosis. | Investigated in the context of IL-1ra effects on cell death. |
| PLAT | Encodes tissue plasminogen activator (alteplase), which can cleave IL-1ra. | Explains timing-dependent loss of IL-1ra neuroprotection in stroke. |
| NLRP3 | Encodes the NLRP3 inflammasome, which drives IL-1β maturation. | Provides context for IL-1ra's role in counterbalancing inflammasome output. |
| IL6 | Encodes interleukin-6, a cytokine often co-regulated with IL-1 pathways. | Used as a downstream inflammatory marker in IL-1ra studies. |
| TNF | Encodes tumor necrosis factor, another major inflammatory cytokine. | Helps contextualize the anti-inflammatory scope of IL-1ra. |
| CXCL8 | Encodes interleukin-8, a chemokine induced by inflammatory signaling. | Can serve as a readout of IL-1 pathway activity modulated by IL-1ra. |
| PTGS2 | Encodes cyclooxygenase-2, an inflammatory enzyme induced by IL-1. | Useful as a downstream marker of IL-1ra-mediated suppression. |
| MMP9 | Encodes matrix metalloproteinase-9, involved in tissue remodeling and inflammation. | Relevant to IL-1-driven tissue damage and its antagonism. |
How Is interleukin-1 receptor antagonist activity Regulated?
The activity of interleukin-1 receptor antagonist (GO:0005152) is regulated at multiple levels. Its availability is influenced by proteolytic cleavage; alteplase can cleave IL-1ra in a timing-dependent manner, impairing its neuroprotective effects in ischemic stroke. Delivery and stability can be improved using injectable biomaterials, which modulate the effective concentration and duration of IL-1ra activity. In addition, the balance between IL-1 agonists and IL-1ra determines the net signaling output, and non-canonical interactions such as binding to CHRM4 can redirect IL-1ra function in specific cellular contexts.
interleukin-1 receptor antagonist activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1RN | IL-1-driven autoinflammation and cytokine imbalance | IL1RN knockout or knock-in cell lines; cytokine release assays. |
| CHRM4 | Prostate cancer immunosuppression and neuroendocrine differentiation | CHRM4 overexpression or knockout in prostate cancer cell lines. |
| PLAT | Ischemic stroke and alteplase-mediated IL-1ra cleavage | PLAT overexpression or point-mutation models in neuronal cells. |
| CASP3 | Cell death pathway modulation by IL-1ra | CASP3 knockout or reporter lines treated with IL-1ra. |
| NLRP3 | Inflammasome-driven IL-1β production | NLRP3 knockout or overexpression models with IL-1ra treatment. |
IL-1ra in inflammatory and autoinflammatory diseases
Because GO:0005152 restrains IL-1 signaling, deficiencies or imbalances in IL-1ra activity are associated with excessive inflammation. Erdheim-Chester disease is an inflammatory histiocytosis in which cytokine pathways, including IL-1, are relevant to disease biology. Understanding IL-1ra function helps explain how endogenous anti-inflammatory mechanisms can fail and how recombinant IL-1ra might be used therapeutically.
IL-1ra in cancer
IL-1ra can promote immunosuppression and neuroendocrine differentiation in prostate cancer through binding to CHRM4, revealing a non-canonical role beyond IL-1 receptor blockade. This suggests that GO:0005152 may contribute to tumor progression in a context-dependent manner, and that targeting IL-1ra interactions could be explored in cancer research.
IL-1ra in ischemic stroke and neuroprotection
In ischemic stroke, IL-1ra has neuroprotective potential, but its cleavage by alteplase impairs this benefit in a timing-dependent way. This highlights how the stability and regulation of IL-1ra activity directly influence clinical outcomes and underscores the need to preserve GO:0005152 function during thrombolytic therapy.
IL-1ra and cell death pathways
Computational studies indicate that IL-1ra can modulate distinct cell death pathways, suggesting that its antagonist activity influences cell survival decisions beyond inflammation. This has implications for diseases where cell death and inflammation intersect, such as neurodegeneration and tissue injury.
From interleukin-1 receptor antagonist activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL1RN increase IL-1 signaling? | IL1RN knockout cell line with IL-1 stimulation and NF-κB readout. |
| Does a specific IL1RN variant alter antagonist activity? | Point-mutation knock-in of IL1RN in a relevant cell line. |
| Can tagged IL-1ra be used to track binding to IL-1R1? | Tagged knock-in of IL1RN for imaging and co-immunoprecipitation. |
| Does IL-1ra binding to CHRM4 affect prostate cancer phenotypes? | CHRM4 overexpression or knockout in prostate cancer cells. |
| Does alteplase cleavage of IL-1ra impair neuroprotection? | PLAT overexpression or point-mutation models in neuronal cells. |
| Can IL-1ra delivery be improved with biomaterials? | Overexpression or controlled-release systems in vitro and in vivo. |
How to Study the interleukin-1 receptor antagonist activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NF-κB reporter assay | Activation of NF-κB downstream of IL-1 receptor | Testing IL-1ra antagonist activity. |
| ELISA | Concentration of cytokines and chemokines | Quantifying suppression of IL-1-induced inflammatory output. |
| Co-immunoprecipitation | Protein-protein interactions | Detecting IL-1ra binding to IL-1R1 or CHRM4. |
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing IL-1ra-receptor interactions. |
| Caspase activity assay | Apoptotic pathway activation | Assessing modulation of cell death by IL-1ra. |
| Flow cytometry | Cell viability and death | Evaluating IL-1ra effects on cell fate. |
| Proteolytic cleavage assay | Susceptibility of IL-1ra to cleavage | Studying alteplase-mediated cleavage in stroke models. |
| Biomaterial release assay | Release kinetics of IL-1ra | Optimizing injectable delivery systems. |
Cytokine and signaling assays
To study GO:0005152, researchers commonly measure IL-1-induced signaling readouts such as NF-κB activation and MAPK phosphorylation in the presence or absence of IL-1ra. ELISA-based quantification of downstream cytokines and chemokines provides a functional readout of antagonist activity.
Binding and interaction studies
Direct binding of IL-1ra to the IL-1 receptor complex or to non-canonical partners such as CHRM4 can be assessed using co-immunoprecipitation, surface plasmon resonance, or computational docking. These methods help define the molecular basis of the antagonist activity.
Cell death and viability assays
Because IL-1ra can modulate distinct cell death pathways, apoptosis and viability assays are used to determine how the antagonist activity influences cell fate. Caspase activity assays and flow cytometry are typical approaches.
Delivery and stability testing
Injectable biomaterials and controlled-release systems are tested to evaluate how delivery affects IL-1ra stability and therapeutic effect. Proteolytic cleavage assays, such as those involving alteplase, are used to assess how cleavage impacts activity.
How CRISPR Can Be Used to Study GO:0005152 interleukin-1 receptor antagonist activity
Knockout
CRISPR knockout of IL1RN can be used to eliminate interleukin-1 receptor antagonist activity, allowing researchers to measure the consequences of unchecked IL-1 signaling. Knockout of downstream signaling genes such as NFKB1 or MAPK1 can help dissect the pathway.
Point Mutation
Point mutations in IL1RN can be introduced to test how specific residues affect antagonist activity, receptor binding, or susceptibility to cleavage. Such models are valuable for linking genotype to functional outcomes.
Knock-in
Knock-in of tagged IL1RN allows tracking of IL-1ra localization, binding, and turnover in live cells. Knock-in of disease-associated variants can model altered antagonist activity in relevant cell types.
Overexpression
Overexpression of IL1RN or CHRM4 can be used to study the effects of excess antagonist activity or non-canonical interactions on inflammation and cancer phenotypes. Overexpression models are also useful for testing delivery and stability of IL-1ra.
How EDITGENE Supports interleukin-1 receptor antagonist activity Research
Researchers studying interleukin-1 receptor antagonist activity-related genes often need to determine whether a candidate gene is causally involved in IL-1 pathway regulation, inflammation, or cancer phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise manipulation of genes such as IL1RN, IL1R1, CHRM4, and downstream signaling components, supporting mechanistic and translational studies of GO:0005152.
Contact EDITGENE today to design your custom CRISPR model for interleukin-1 receptor antagonist activity research.
Frequently Asked Questions About interleukin-1 receptor antagonist activity
What is interleukin-1 receptor antagonist activity?
It is a molecular function (GO:0005152) that blocks the binding of interleukin-1 to the interleukin-1 receptor complex, thereby dampening IL-1 signaling.
What genes are involved in interleukin-1 receptor antagonist activity?
The key gene is IL1RN, which encodes IL-1ra; related genes include IL1B, IL1A, IL1R1, IL1RAP, and CHRM4.
What is the GO ID for interleukin-1 receptor antagonist activity?
The GO ID is GO:0005152.
How does IL-1ra block IL-1 signaling?
IL-1ra competitively occupies the IL-1 receptor complex without activating it, preventing IL-1α and IL-1β from initiating NF-κB and MAPK signaling.
Is IL-1ra the same as anakinra?
Anakinra is a recombinant form of the interleukin-1 receptor antagonist used therapeutically to harness this activity.
Can IL-1ra bind to targets other than the IL-1 receptor?
Yes, IL-1ra can bind CHRM4, which has been linked to immunosuppression and neuroendocrine differentiation in prostate cancer.
How is IL-1ra activity regulated?
It can be regulated by proteolytic cleavage, such as alteplase-mediated cleavage in ischemic stroke, and by delivery systems that affect its stability.
What diseases are associated with IL-1ra dysfunction?
Inflammatory and autoinflammatory conditions, prostate cancer, and ischemic stroke have been linked to altered IL-1ra activity.
How can CRISPR be used to study IL-1ra?
CRISPR knockout, point mutation, knock-in, and overexpression of IL1RN and related genes allow functional dissection of GO:0005152.
What methods measure interleukin-1 receptor antagonist activity?
NF-κB reporter assays, ELISAs, co-immunoprecipitation, caspase assays, and cleavage assays are commonly used.
Conclusion
Interleukin-1 receptor antagonist activity (GO:0005152) is a critical molecular brake on IL-1 signaling, mediated primarily by IL1RN and its product IL-1ra. Its importance spans inflammation, cancer, and neuroprotection, with emerging evidence for non-canonical interactions and regulation by proteolysis. Studying this activity with CRISPR-based models and functional assays can clarify disease mechanisms and support therapeutic development.
References
- 1. Lennard AC. 2017. lnterleukin-1 Receptor Antagonist.. Crit Rev Immunol 37(2-6):531-559 PMID: 29773033
- 2. Liu YN et al.. 2024. Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.. Cancer Lett 598:217090 PMID: 38945201
- 3. Yazdi AS et al.. 2016. The Interleukin-1 Family.. Adv Exp Med Biol 941:21-29 PMID: 27734407
- 4. Dinarello CA. 1997. Interleukin-1.. Cytokine Growth Factor Rev 8(4):253-65 PMID: 9620641
- 5. Spinello A et al.. 2019. How Can Interleukin-1 Receptor Antagonist Modulate Distinct Cell Death Pathways?. J Chem Inf Model 59(1):351-359 PMID: 30586302
- 6. Clements AEB et al.. 2019. Injectable biomaterials for delivery of interleukin-1 receptor antagonist: Toward improving its therapeutic effect.. Acta Biomater 93:123-134 PMID: 31029831
- 7. Mosneag IE et al.. 2026. Timing-Dependent Cleavage of Interleukin-1 Receptor Antagonist by Alteplase Impairs Neuroprotection in Ischemic Stroke.. Stroke 57(6):1777-1791 PMID: 41847765
- 8. Brychtová M et al.. 2021. Erdheim-Chester disease.. Klin Onkol 34(6):434-439 PMID: 34911328
